BCR/ABL fusion tyrosine kinase is responsible for the initiation and maintenance of the Philadelphia chromosome (Ph 1 )-positive chronic myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias (ALL). STI571 (Gleevec), a novel anti-leukemia drug targeting BCR/ABL kinase can induce remissions of the Ph 1 -positive leukemias. STI571 was recently combined with the standard cytostatic drugs to achieve better therapeutic results and to overcome emerging drug resistance mechanisms. We decided to search for a more specific partner compound for STI571. Our previous studies showed that a signaling protein phosphatidylinositol-3 kinase (PI-3k) is essential for the growth of CML cells, but not of normal hematopoietic cells (Blood, 86:726,1995) . Therefore the anti-Ph 1 -leukemia effect of the combination of BCR/ABL kinase inhibitor STI571 and PI-3k inhibitor wortmannin (WT) or LY294002 (LY) was tested. We showed that STI571+WT exerted a synergistic effect against the Ph 1 -positive cell lines, but did not affect the growth of Ph 1 -negative cell line. Moreover, the combinations of STI571+WT or STI571+LY were effective in the inhibition of clonogenic growth of CML-chronic phase and CML-blast crisis patient cells, while sparing normal bone marrow cells. Single colony RT -PCR assay showed that colonies arising from the mixture of CML cells and normal bone marrow cells after treatment with STI571+WT were selectively depleted of BCR/ABLpositive cells. Biochemical analysis of the CML cells after the treatment revealed that combination of STI571+WT caused a more pronounced activation of caspase-3 and induced massive apoptosis, in comparison to STI571 and WT alone. In conclusion, combination of STI571+WT or STI571+LY may represent a novel approach against the Ph
Introduction
The Philadelphia chromosome (Ph 1 ) is present in virtually all cases of chronic myelogenous leukemia (CML) and in 20% of cases of acute lymphocytic leukemia (ALL) (Faderl et al., 1999; Sawyers, 1999) . This translocation is characterized by the formation of bcr/abl hybrid genes derived from relocation of the cabl gene from chromosome 9 to the bcr gene locus on chromosome 22. The bcr/abl hybrid genes produce BCR/ABL fusion proteins p210 and p185 kd that transform immature hematopoietic cells in vitro and cause a chronic myelogenous leukemia or acute leukemia-like syndromes in mice (Van Etten, 2001) . Almost all patients with CML express the p210 BCR/ ABL protein, whereas in 50% of adults and 80% of children with Ph 1 -positive ALL the p185 BCR/ABL is detected (Faderl et al., 1999; Sawyers, 1999) .
CML is a clonal disorder arising from neoplastic transformation of hematopoietic stem cell by the p210 BCR/ABL kinase (Faderl et al., 1999; Sawyers, 1999) . The typical course of CML involves progression from a protracted chronic phase (CML-CP) to an accelerated phase with duration of 1 -1.5 years followed by a rapidly fatal blastic phase (CML-BC). In the chronic phase, the disease process is characterized by increased numbers of immature myeloid precursors in bone marrow, peripheral blood, spleen, and liver. Myeloid precursors retain the ability to terminally differentiate so that the hallmark of the disease is a marked granulocytosis. The transition from chronic phase to blast crisis is characterized by a dramatic increase in the number of blast cells in hematopoietic tissues. Such cells exhibit proliferative advantage over normal cells and loss of differentiation potential. Blast crisis is usually of myeloid phenotype but in about 30% of patients, a lymphoid phenotype is seen. In addition to the lymphoid CML-BC Ph 1 -positive ALL may arise as a direct result of the t(9;22) translocation occurring in the lymphocytic precursor cell. In such case, p185 kd BCR/ABL tyrosine kinase is produced.
Current therapies for CML include allogeneic bone marrow transplantation (AlloBMT) and drug regimens including interferon (IFN)-alpha (Silver et al., 1999) . AlloBMT, the only curative treatment for CML, is associated with substantial morbidity and mortality and is limited to patients for whom a suitable donor is available. IFN-alpha prolongs overall survival but has serious adverse effects. Thus, the overall cure rate for CML is less than 20%. CML-BC is highly refractory to treatment. The rate of response to standard induction chemotherapy in patients with myeloid blast crisis is approximately 20%, and the rate of complete remission is less than 10%. In patients with lymphoid blast crisis, the rate of response is approximately 50%, but remissions are short-lived (Sacchi et al., 1999; Talpaz et al., 1987) . AlloBMT during blast crisis induces fiveyear survival in only 6% of patients (Clift and Storb, 1996; Gratwohl and Hermans, 1996) . Ph 1 -positive ALL also has a poor prognosis (Arico et al., 2000; Copelan and McGuire, 1995) .
STI571, a recently developed ABL kinase inhibitor, is a very promising oncogene-targeting compound, but does not provide an ultimate cure of Ph 1 leukemias (Druker and Lydon, 2000; Druker et al., 1996; Schindler et al., 2000) . Leukemia cells become resistant to the drug (Gorre et al., 2001; le Coutre et al., 2000; Mahon et al., 2000; Weisberg and Griffin, 2000) , in addition STI571-induced plasma protein alpha1 acid glycoprotein binds to STI571 and reduces effectiveness of the long-term treatment (Gambacorti-Passerini et al., 2000) . More recently, combination of STI571 with commonly used anti-leukemic agents was shown to exert increased cytotoxic effect against BCR/ABLpositive cell lines and CML cells as compared with STI571 alone (Fang et al., 2000; Kano et al., 2001; Thiesing et al., 2000; Topaly et al., 2001) . These reports are in agreement with our previous findings that downregulation of BCR/ABL by the antisense oligodeoxynucleotides combined with cyclophosphamide exerted synergistic anti-leukemic effect (Skorski et al., 1993 (Skorski et al., , 1997b . Thus, combinations of BCR/ABL inhibitors with anti-leukemic drugs may have improved efficacy against Ph 1 -positive leukemias. Although promising, these protocols suffer from the therapeutic limitations and adverse effects associated with the cytostatic drugs.
We made an attempt to combine STI571 with a compound exerting selective anti-leukemic activity. Based on our previous findings (Skorski et al., 1995b (Skorski et al., , 1996 it seemed reasonable to target one of the BCR/ ABL downstream signaling proteins, which is essential for BCR/ABL-mediated leukemogenesis. BCR/ABL proteins possess constitutive tyrosine kinase activity, necessary for their leukemogenic potential (Lugo et al., 1990) . Cytoplasmic BCR/ABL proteins (Dhut et al., 1990) exert their oncogenic potential in cooperation with numerous cytoplasmic and nuclear effectors (Raitano et al., 1997; Sattler and Salgia, 1997) . Several major signaling pathways are engaged by BCR/ABL leading to the activation of such proteins as: RAS (Goga et al., 1995; Pendergast et al., 1993; Puil et al., 1994; Sawyers et al., 1995; Skorski et al., 1994) , MAPK (Kang et al., 1999 (Kang et al., , 2000 , STAT5 (de Groot et al., 1999; Horita et al., 2000; Nieborowska-Skorska et al., 1999; Sillaber et al., 2000) and PI-3k (Neshat et al., 2000; Skorski et al., 1995a Skorski et al., , 1997a Varticovski et al., 1991) . RAS, MAPK and STAT5 are important for the growth of normal and Ph 1 -positive hematopoietic cells (de Groot et al., 1999; Kolonics et al., 2001; Skorski et al., 1992 Skorski et al., , 1994 Teglund et al., 1998; Welham et al., 1992) . PI-3k represents a unique signaling molecule since it is required only for the proliferation of BCR/ ABL-dependent leukemic cells but not of normal hematopoietic cells (Skorski et al., 1995a) . PI-3k is a heterodimer consisting of p85 kd and p110 kd subunits (Fry and Waterfield, 1993) . p110 catalytic subunit is stimulated as a result of interaction of p85 adaptor subunit with activated tyrosine kinase. PI-3k catalyzes the phosphorylation of inositol phospholipids in the D-3 position of their inositol ring (Carpenter and Cantley, 1996; Stephens et al., 1993) , which plays an important role in regulation of several cell functions including apoptosis and proliferation (Hawkins et al., 1997; Toker and Cantley, 1997 Next we tested if PI-3k inhibitor or MEK1 inhibitor could enhance the anti-leukemia activity of STI571. For this reason Ph 1 -positive cell lines EM2 (p210 BCR/ABL, myeloid CML-BC), BV173 (p210 BCR/ ABL, lymphoblastic CML-BC) and ALL-1 (p185 BCR/ABL, ALL), and Ph 1 -negative HL60 cell line (AML) were treated in vitro with STI571, WT, PD98059 or the combination of STI571+WT or STI571+PD98059 in the concentrations exhibiting partial inhibitory effect. Control groups were incubated with the diluents only. Cells surviving the treatment were detected by clonogenic assay in methylcellulose ( Figure 2 ). Growth of EM2 cells was significantly affected by the low concentrations (STI571=1 mM, WT=12.5 nM) of individually applied compounds, but the combination exerted even more pronounced effect and eliminated almost completely the clonogenic potential of these cells. BV173 and ALL-1 cells were not affected or were only modestly inhibited by STI571 and WT applied individually. However, the combination exerted strong anti-proliferative effect. two-fold higher concentrations of STI571 (2 mM) and WT (25 nM) were used to achieve substantial inhibitory effect against BV173 and ALL-1 cell lines. Even in these conditions STI571+WT exerted much better inhibitory effect than the individual agent. In contrast to Ph 1 -positive cell lines HL60 cells were not significantly affected either by STI571, WT or STI571+WT. Combination of STI571+PD98059 did not exert better anti-proliferative effect in comparison to STI571 or PD98059 alone in both EM2 and HL60 cells.
PI-3k inhibitors enhanced the selective elimination of CML cells by STI571
Six CML-BC, four CML-CP and four NBMC cell samples were used to evaluate the effectiveness of combination application of STI571+WT for the treatment of primary leukemia cells. Cells were Table 1 and summarized in Figure 3 (left panel). In general, in the presence of growth factor STI571 (1 mM) and WT (12.5 nM) exerted modest anti-CML -BC effect: 46.9+8.5% and 61.3+5.3% of the clonogenic cells survived the treatment. Combination of STI571+WT had much stronger effect and spared only 15.0+2.9% of clonogenic cells. When cells were treated in the absence of growth factor the inhibitory effect of STI571 or WT was more pronounced: 27.5+8.3% and 31.5+9.9% of cells survived individual treatment, in comparison to only 6.3+2.6% surviving the combination treatment.
CML-CP cells were treated with STI571 or/and WT in the presence of GM-CSF. When the results from individual patient samples were pooled together the combination of STI571+WT did not exert statistically significant better inhibitory effect in comparison to the individual agents: 54.3+11.8%, 47.3+14.2% and 26.8+12.5% of clonogenic cells survived the treatment with STI571, WT and STI571+WT, respectively. However, two patients (CP-1 and CP-2) responded positively to the combination treatment, whereas two others (CP-3 and CP-4) did not (see Table 1 ).
NBMC were resistant to STI571, WT and STI571+WT in the presence or absence of GM-CSF. In comparison to control cells treated with the diluents, 103.6+2.8%, 92.4+2.2% and 92.2+1.2% of clonogenic cells were spared after STI571, WT and STI571+WT treatment, respectively.
Another PI-3k inhibitor LY294002 was used in combination with STI571 to confirm that PI-3k inhibitor can facilitate anti-leukemic activity of STI571. In general, the results are in agreement with those obtained using STI571+WT (Table 2 and Figure  3 , right panel). Only 5.8+2.9% of CML-BC cells from the pooled samples survived STI571+LY (1 mM and 2 mM, respectively) treatment in comparison to 32.8+9.8% and 37.3+9.0% after STI571 or LY, respectively. Analysis of the CML-CP pooled samples did not show a significant advantage of the combination treatment over the individual treatment: 31+10.7% of the clonogenic cells survived STI571+LY in comparison to 54.5+11.9% and 59.5+15.2% spared by STI571 or LY, respectively. Again, CML-CP cells from patients CP-1 and CP-2 responded significantly better to the combination treatment than those from patients CP-3 and CP-4 (14.5+9.5% and 49.0+1.0% surviving clonogenic cells, respectively). STI571+LY exerted only a minor effect on the clonogenic activity of NBMC (87.0+0.6% clonogenic cells survived). (Figure 4) . Control mixture contained 46.6% BCR/ ABL-positive colonies. Although STI571 (1 mM) or WT (12.5 nM) reduced this number to 26.0 and 34.0% respectively, the combination treatment left only 1.0% BCR/ABL-positive colonies. According to our previous studies BCR/ABL-negative colonies are also Ph 1 -negative (Skorski et al., 1993) .
WT facilitated apoptosis in STI571-treated CML cells
The inhibitory activity of STI571 or/and WT in CML-BC cells cultured in the presence or absence of GM-CSF was assessed by Western analysis (total tyrosine phosphorylated proteins, phospho-Akt and phosphoS6k) and by PI-3k assay (in vitro catalytic activity) ( Figure 5, left panel) . As expected, STI571 inhibited BCR/ABL kinase and as a consequence also PI-3k, but WT downregulated only PI-3k activity. Simultaneous application of both agents exerted stronger inhibitory effect on the total tyrosine phosphorylated proteins and PI-3k catalytic activity. Inhibition of PI-3k catalytic activity was accompanied by inactivation of its downstream effectors: Akt and S6k (assessed by Western analysis detecting activated forms of these kinases).
Inhibition of BCR/ABL kinase and PI-3k correlated nicely with the activation of caspase-3 ( Figure 5 , left panel) and reduction of the CML clonogenic cells (Table  1 and Figure 3 , left panel). Thus, apoptosis induced by STI571, WT and STI571+WT was assessed and compared using in vitro apoptosis detection kit ( Figure  5 , right panel). Both agents applied individually induced apoptosis in CML-BC cells, but combination treatment triggered a more pronounced effect.
Discussion
Recent clinical trials with STI571 (Gleevec, imatinib mesylate), a specific inhibitor of the BCR/ABL kinase, (7) or presence (+) of GM-SCF. Control cells were incubated with PBS+DMSO. (a) Twelve hours later total cell lysates were obtained and examined by Western analysis to detect tyrosine-phosphorylated proteins (P-Tyr), S6 kinase phosphorylated on Thr412 (P.S6k) and total S6 kinase, Akt kinase phosphorylated on Ser473 (P.Akt) and total Akt kinase, and activated caspase-3. PI-3k activity was measured by detection of PI3P. (Druker et al., 2001a,b) . However, relapses have been a growing problem in patients with CML-BC as well as ALL (Druker et al., 2001a) , primarily because of the resistance to STI571 (Gambacorti-Passerini et al., 2000; Gorre et al., 2001; Hofmann et al., 2002; le Coutre et al., 2000; Mahon et al., 2000; von Bubnoff et al., 2002; Weisberg and Griffin, 2000) . In this study, combinations of STI571 with PI-3k inhibitors were investigated to determine whether this approach would enhance the antileukemic activity of STI571. PI-3k was chosen as a second target because of our previous report that wortmannin (PI-3k inhibitor) selectively eliminates Ph 1 -positive cells (Skorski et al., 1995a) and of additional evidence implicating PI-3k in BCR/ABL signaling Neshat et al., 2000) . Thus, the combination of STI571 and WT (or another PI-3k inhibitor LY294002) might exert a highly specific therapeutic effect.
Results showed that the growth of Ph 1 -positive cell lines was inhibited more effectively by STI571+WT than by the individual agent, implicating synergistic activity of STI571 and WT against Ph 1 -positive cells. Interestingly Ph 1 -negative HL60 cells were not affected. Ph 1 -positive lymphoid cell lines BV173 and ALL-1 required higher concentrations of STI571 and WT in comparison to Ph 1 -positive myeloid EM2 cells. This is in agreement with the general observation that Ph 1 -positive lymphoid cells are less sensitive to STI571 and other drugs than their myeloid counterparts (Druker et al., 2001a; Kano et al., 2001) . PI-3k inhibitors (WT and LY) increased also the effectiveness of STI571 against CML cells, but not against normal hematopoietic cells. This effect could be predicted from the previous studies demonstrating that STI571 and WT selectively inhibit Ph 1 -positive cells, but not their normal counterparts (Druker et al., 1996; Marley et al., 2000; Skorski et al., 1995a) .
CML-BC and CML-CP cells demonstrated different sensitivity to STI571+WT and STI571+LY. While all tested CML-BC samples responded favorably to the combination, only in half of CML-CP cases PI-3k inhibitors increased the anti-leukemic effect of STI571. This differential sensitivity of CML-CP cells to the combination could be dependent on the stage of CML-CP (at diagnosis or shortly before malignant acceleration). Theoretically, cells in early CP stage may depend mostly on the anti-apoptotic mechanisms, whereas as cells progress toward accelerated phase the pathways stimulating protection from apoptosis and proliferation may become equally important (Gordon et al., 1999) , which can sensitize these cells to the combination treatment. Thus, if STI571+WT/LY is considered as a novel treatment against CML-CP, its efficacy should be individually pre-tested.
The mechanism of synergistic/additive effect of the inhibitors of BCR/ABL kinase and PI-3k may depend on the inefficient inhibition of the ABL kinase by STI571. PI-3k is a downstream effector of BCR/ABL, therefore, STI571 should inhibit BCR/ABL and as a secondary effect also PI-3k (Neshat et al., 2000; Skorski et al., 1995a Skorski et al., , 1997a Varticovski et al., 1991) . In fact, STI571 caused partial inhibition of PI-3k activity (this work). The incomplete inactivation of PI3k may be due to the low dose of STI571 or the development of BCR/ABL-independent pathways activating PI-3k. The former speculation is supported by the fact that STI571 is a reversible inhibitor working in a dose-dependent manner and that CML-BC cells usually express high levels of BCR/ABL (Gaiger et al., 1995; Schindler et al., 2000; Wetzler et al., 1993) . The latter hypothesis is based on the finding that activation of PI-3k, like STAT5, could become independent of BCR/ABL (Donato et al., 2001; Klucher et al., 1998) . In both situations combination of STI571+WT/LY should exert better anti-leukemia effect than the individual agent. In addition, a sub-population of CML cells may become resistant to STI571, because of a mutation in the BCR/ABL kinase domain (Gorre et al., 2001; Hofmann et al., 2002; von Bubnoff et al., 2002) . These mutations might be facilitated by the genomic instability phenotype of the BCR/ABL cells (Canitrot et al., 1999; Klucher et al., 1998; Salloukh and Laneuville, 2000) .
PI-3k inhibitors appear to exert a selective antileukemia effect (Skorski et al., 1995a and this work) but the reason for this effect is not known. The simplest explanation is that interaction between growth factors and their membrane receptors in normal bone marrow cells induce PI-3k-dependent and PI-3k-independent pathways leading to the survival and growth (Kulik and Weber, 1998; Peruzzi et al., 1999) . Conversely, in CML cells BCR/ABL decreases the expression of growth factor receptors (common b-chain of the IL-3/GM-CSF receptor), thus signaling to the proteins regulating apoptosis and cell cycle is more (but not exclusively) dependent on BCR/ABL -PI-3k pathway (Donato et al., 2001; Gesbert et al., 2000; Neshat et al., 2000) .
Although combination of STI571 with an inhibitor of BCR/ABL downstream effector is a reasonable strategy to inhibit Ph 1 -positive leukemias, the choice of downstream target molecule should be based on solid experimental data comparing BCR/ABL-and growth factor-dependent signaling (Raitano et al., 1997; Sattler and Salgia, 1997) . For example, targeting major signaling molecules such as RAS or STAT5 may be associated with a significant side effect in normal cells (Ilaria et al., 1999; Skorski et al., 1992) . Moreover, although recent studies revealed that targeting of JAK2 enhanced the effect of STI571 against BCR/ABLpositive cell lines ), JAK2 was not found consistently activated in BCR/ABL-positive cells (Carlesso et al., 1996; Chai et al., 1997; Ilaria and Van Etten, 1996; Xie et al., 2001) , limiting eventual application of this approach to individual cases. In addition, even if Sos -Grb2 -RAS -RAF -MAPK pathway seems to play an important role in BCR/ ABL cells (Kardinal et al., 2001) , simultaneous targeting of the MAPK activator MEK1 and BCR/ Targeting BCR/ABL and PI-3k in Ph 1 -leukemias A Klejman et al ABL produced mixed results. MEK1 inhibitors worked synergistically with STI571 to induce apoptosis in BCR/ABL-positive cell lines K562 and LAMA 84 (Yu et al., 2002) , but not in EM2 (this work). This discrepancy can be eventually explained by the variabilities between cell lines, but the efficiency of simultaneous targeting of BCR/ABL+MEK1 should be confirmed in the primary leukemia cells.
Altogether, PI-3k seems to be a good target of choice for combination treatment of Ph 1 -positive leukemias because of the selective anti-leukemia activity of its inhibitors in the experimental conditions (Skorski et al., 1995a, and this work) . The apparent lack of evident toxicity of PI-3k inhibitors for normal hematopoietic cells does not eliminate the possibility that the inhibitors may exert significant negative effects in other cell types and tissues, because PI-3k is widely used as a signaling molecule (Katso et al., 2001) . In addition, the available inhibitors: LY294002 and especially wortmannin may exert non-specific effects by inhibition of other molecules, for example p38 MAPK (Somwar et al., 2001) , KIT (Timokhina et al., 1998) , erythropoietin (Haseyama et al., 1999) or IL-2 (Nielsen et al., 1996) . Thus, further studies are warranted to determine the biological consequences of inhibition of PI-3k by these compounds in various cells and tissues. Similar results obtained with the combinations of STI571+WT and STI571+LY suggested that both PI-3k inhibitors exert their effect via inhibition of PI-3k catalytic activity, especially because LY294002 seems to exert less non-specific effects that WT (Somwar et al., 2001) . Eventually, more specific inhibitors of PI-3k should be developed. At this time, the combination of STI571+WT/LY may be applicable for bone marrow purging, but probably not for in vivo treatment.
In conclusion, we showed that PI-3k inhibitors WT and LY could enhance anti-leukemia effect of STI571 in certain conditions. The effect was seen in all CML-BC samples and in half of the CML-CP samples tested. This finding may be useful for the planning of more effective treatment for CML-BC, which is refractory to various therapeutic approaches. In addition, PI-3k appears to be important for the growth of hematological malignancies induced by other oncogenic tyrosine kinases such as TEL/ABL, TEL/JAK2, TEL/ PDGFbR, NPM/ALK and MEN2-RET (Nguyen et al., 2001; Segouffin-Cariou and Billaud, 2000; Slupianek et al., 2001) . Thus, treatment consisting of the inhibitor of oncogenic kinase and of PI-3k may have a broad spectrum of applications.
Materials and methods

Cells
Bone marrow cells (BMCs) were obtained after informed consent by aspiration from the iliac crest of healthy volunteers (normal BMC=NBMC) and from patients with CML-chronic phase (CML-CP) or CML-blast crisis (CML-BC). Mononuclear cells (MNC) were separated on Histopaque -1077 density gradient (Sigma Chemical Co., St. Louis, MO, USA) and enriched for hematopoietic progenitors after removing of the majority of adherent cells and T lymphocytes (A-T-MNC) as described (Skorski et al., 1992) . EM2 and BV173 cell lines carrying t(9;22) chromosomal translocation and expressing p210 BCR/ABL protein were established from the patients with CML-BC of the myeloid and lymphoid origin, respectively. ALL-1 cell line was established from the Ph 1 -positive ALL patient and express p185 BCR/ABL protein. HL60 is a BCR/ABLnegative acute myeloid leukemia (AML) cell line. Cell lines were maintained in RPMI supplemented with 10% FBS, 2 mM L-glutamine and penicillin/streptomycin (100 mg/ml each).
Reagents STI571 was generously provided by Novartis Pharma AG (Basel, Switzerland) and prepared as 10 mM stock solution in PBS. PI-3k inhibitors: wortmannin and LY294002 (both from Sigma Chemical Co., St. Louis, MO, USA) were prepared as 12.5 and 3 mM stocks (wortmannin) and 1 mM stock (LY294002) in DMSO. MEK1 inhibitor PD98059 (Cell Signaling Technology, Inc., Beverly, MA, USA) was dissolved in DMSO to the concentration of 50 mM.
Treatment with the inhibitors
Primary cells (10 5 /ml of Iscove's Modified Dulbecco Medium (IMDM) supplemented with 10% FBS, L-glutamine and antibiotics) were incubated in the absence or presence of 10 U/ml of the recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (Genetics Institute, Cambridge, MA, USA). Cell lines were incubated in RPMI supplemented with 10% FBS, L-glutamine and antibiotics. Single dose of ABL kinase inhibitor STI571 or MEK1 inhibitor PD98059 was added at time 0, and PI-3k inhibitors wortmannin or/and LY294002 were added three times at 0, 12 and 24 h, as described (Skorski et al., 1995a) . Appropriate control group with diluents only were included. After 48 h 10 4 primary cells and 10 3 cell lines cells were plated in methylcellulose (MethoCult H4230, StemCell Technologies Inc., Vancouver, BC, Canada). Colonies were counted after 7 -10 days. Apoptotic cells were detected on cytospin slides by TACS in situ apoptosis detection kit (Trevigen, Inc., Gaithersburg, MD, USA).
PI-3 kinase assay
PI-3k activity was examined in the anti-phosphotyrosine immunoprecipitates using [g-32 P]ATP and phosphatidylinositol (PI) as a substrate as described (Skorski et al., 1995a) . 32 P-labeled PI (PI3P) was resolved by thin layer chromatography and visualized by autoradiography.
Single colony reverse transcriptase-polymerase chain reaction (RT -PCR) analysis CML-BC cells were mixed 1 : 1 with NBMCs and treated with STI571, WT or with the combination of STI571+WT as described above. Diluents (PBS and DMSO) were added to control group. After the treatment cells were plated in methylcellulose in the presence of GM-CSF. Single colonies were picked separately and the expression of BCR/ABL and b-actin mRNA in each colony was examined by RT -PCR followed by Southern analysis of the amplified products as described (Skorski et al., 1993) .
